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Abstract 
The type 1 iodothyronine d iodinase (1D-I) in liver and kidney converts the prohormone 
thyroxine ('1"4) by outer ing deiodination (ORD) to bioactive 3,3',5-triiodothyronine (T3) or 
by inner ring deiodination (IRD) to inactive 3,3',5-"triiodothronine (rT3), while it also 
catalyzes the IRD of T3 and the ORD of rT 3, with the latter as the preferred substrate. Sulfa- 
tion of the phenolic hydroxyl group blocks the ORD of T 4, while it strongly stimulates the 
IRD of both T 4 and T3, indicating that sulfation is an important step in the irreversible inac- 
tivation of thyroid hormone. This review summarizes recent studies concerning this interac- 
tion between sulfation and deiodination of iodothyronines, the characterization of
iodothyronine sulfotransferase activities, the measurement of iodothyronine sulfates in hu- 
mans and animals, and the possible physiological importance of iodothyronine sulfation. 
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Under normal conditions the prohormone thyroxine (3,3',5,5'-tetraiodothyron- 
ine, T4) is the predominant product secreted by the thyroid gland. T4 is converted 
in peripheral tissues by outer ring deiodination (ORD) to the bioactive form of the 
thyroid hormone 3,3',5-triiodothyronine (T3) or by inner ring deiodination (IRD) 
to the inactive metabolite 3,3 ',5 '-triiodothyronine (reverse T3, rT3) (Fig. 1). Both 
T 3 and rT3 are further deiodinated to inactive products, especially 3,3'- 
diiodothyronine (3,3'-T2), which is generated by IRD of T 3 and by ORD of rT 3 
(Fig. 1). Thus, the bioactivity of the thyroid hormone is controlled by competing 
ORD (activation) and IRD (inactivation) pathways [1,2]. 
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Fig. I. Stepwise deiodination f T 4 by ORD to T 3 and by IRD to rT  3, and further by IRD of T 3 and 
ORD of rT 3 to 3,3'-T 2. 
Besides deiodination, glucuronidation and sulfation of the phenolic hydroxyl 
group are other important pathways of iodothyronine metabolism [2,3]. The gluc- 
uronides are stable conjugates which are rapidly excreted in the bile [3]. However, 
the sulfates are rapidly deiodinated in the liver, and little of these conjugates i nor- 
mally excreted intact in the bile or appears in the serum [3,4]. Sulfation strongly 
facilitates the IRD of T4 and T 3, whereas the ORD of T4 sulfate (T4S) is inhibited, 
suggesting that sulfate conjugation isa primary step leading to the irreversible inacti- 
vation of thyroid hormone. 
1. Sul fat ion of  iodothyronines 
Although sulfation of T3 and other iodothyronines in rats has been known for a 
long time, little work has been done to characterize the sulfotransferases (STs) in- 
volved until recently (for a review, see [5]). Sekura et al. [6] have tested the sulfation 
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of a variety of iodothyronine derivatives by purified rat liver aryl sulfotransferase 
(AST) I and AST IV with an assay utilizing 100 #M [35S]PAPS and 50 #M sub- 
strate. AST I and AST IV showed similar sulfation rates with T3 but varying activi- 
ties with other iodothyronines. The substrate preferences of these enzymes 
overlapped for some compounds (e.g. 3,3'-T 2 > T 3 > rT3 > T4, with T4 sulfation 
being undetectable in both cases), but differed markedly for others (e.g. 3-T1 and 
3'-T0. Km and Wma x values were not determined in this study [6]. 
With a standard assay utilizing 0.4 #M [35S]PAPS and 150 #M T 3, Young et al. 
[7] have demonstrated that the hormone is a substrate for at least three phenol 
sulfotransferases (PSTs) in human tissues: two forms of thermostable (TS) PST and 
a thermolabile (TL) PST. Of these, TS PST is especially abundant in the liver, while 
TL PST is more prevalent in the intestine. In keeping with the prominent role of TS 
PST, T 3 sulfation in human liver was inhibited by low concentrations of 2,6- 
dichloro-4-nitrophenol (DCNP; IC50 ~-5 /~M), a selective inhibitor of this isoen- 
zyme [7]. Sulfate conjugation of T3 was also inhibited by T 4 (IC50 ~ 150 #M), but 
sulfation of T 4 was not tested. Reported K m values amounted to 100-200 #M for 
T 3 and 0.1-0.4 #M for PAPS with the different isolated isoenzymes as well as with 
crude human liver cytosol [7]. 
Gong et al. [8] have recently reported on the measurement of hepatic T3 ST activ- 
ity in different species with a method similar to that of Sekura et al. [6], employing 
50 #M substrate and 200 #M [aSS]PAPS. A marked sex difference was found in 
rats, where T 3 ST activities were 2-5-fold higher in male than in female animals, 
which was related to the different growth hormone secretion patterns in males and 
females. The opposite was found in mice, in that T 3 sulfation rates were 5-fold 
higher in female than in male animals, while no sex-related difference was found in 
human liver T 3 ST activity [8]. In agreement with the results of Sekura et al. [6], 
using AST I and AST IV, iodothyronine sulfation rates in rat liver cytosol were in 
the order T3 > rT3 > "1"4; sulfation of 3,3'-T2 was not tested [8]. The involvement 
of an enzyme homologous to human TS PST was suggested by the finding that T 3 
sulfation in rat liver cytosol is inhibited by low concentrations of DCNP (IC50 5.5 
#M) and pentachlorophenol (IC50 0.065 #M) [81. 
Hurd et al. [9] reported recently, in abstract form, on T3 ST activities in different 
rat tissues using unspecified concentrations of unlabeled PAPS and T 3, measuring 
the production of T3S by specific radioimmunoassay. T 3 sulfation rates were 
highest in liver followed by brain and kidney. Hepatic T 3 ST activity was relatively 
heat stable, showing a Krn value for T 3 of 114 #M. 
In conclusion, sulfation of T 3 and other iodothyronine derivatives i catalyzed by 
multiple PST isoenzymes in liver and other tissues in various pecies. Both in human 
and rat liver, T 3 ST activity is associated largely with thermostable forms of PST 
which are sensitive to inhibition by DCNP. The higher rate of T 3 sulfation in male 
vs. female rats suggests that AST IV is a major T 3 ST in rat liver. However, the con- 
tribution of different isoenzymes to the sulfation of T 3 and analogs both in humans 
and in rats remains to be established. It is remarkable that T4 is a poor substrate 
for all ST activities tudied so far. 
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2. Deiodination of iodothyronine sulfates 
Three thyroid hormone-deiodinating enzymes have been identified, of which the 
type I iodothyronine deiodinase (ID-I) is present in liver, kidney and thyroid [1,2]. 
It is a transmembrane s lenoenzyme located in the endoplasmic reticulum of liver 
cells, which requires thiols such as dithiothreitol (DTT) as the cofactor, and has both 
ORD and IRD activity [1,2,10]. Although ID-I shows preference for rT 3 as the sub- 
strate, its most important physiological purpose is the peripheral production of T 3 
from T4. The type II iodothyronine deiodinase (ID-II) is present predominantly in
the brain, pituitary and brown adipose tissue [1,2]. ID-II has only ORD activity, and 
is an important enzyme for local intracellular T 3 production in these tissues. The 
type III iodothyronine deiodinase (ID-III) is also found in brain but also in skin and 
in the placenta [1,2]. It has only IRD activity and seems a major site for the degrada- 
tion of T 4 and T 3. 
Although T 4 itself may be deiodinated by ID-I either in the outer ring to T 3 or 
in the inner ring to rT 3, this is changed ramatically after sulfate conjugation [11]. 
The IRD of TaS is accelerated about 200 times due to a decrease in apparent Km 
value as well as an increase in Vma x (Table 1). However, ORD of T4S is undetec- 
table, which excludes that T 4 is converted to T 3 by an alternative route via their 
sulfoconjugates. 
ID-I deiodinates primarily the inner ring of T 3, a reaction which is also markedly 
stimulated by sulfoconjugation [12]. The facilitated I RD of T3S is characterized by 
a -30-fold increase in Vma x with little effect on the apparent Km value (Table 1). 
We have observed similar effects of sulfation on the deiodination of T 3 by the type 
I deiodinase in human liver [13]. 
As mentioned above, rT 3 is the preferred ID-I substrate; its ORD to 3,3'-T2 is 
catalyzed > 100-fold more effectively than that of any other known non-sulfated 
Table 1 
Effects of sulfation on deiodination of iodothyronines by rat liver type I deiodinase 
Substrate Deiodination Product K m Vmax Wmax/Km 
T 4 ORD T 3 2.3 30 13 
T4S ORD T3S undetectable 
T 4 IRD rT 3 1.9 18 9 
T4S IRD rT3S 0.3 527 1817 
T 3 IRD 3,3 '-T 2 6.2 36 6 
T3S IRD 3,3 '-T2S, 4.6 1050 230 
rT 3 ORD 3,3'-T 2 0.06 559 8730 
rT3S ORD 3,3'-T2S 0.06 516 8600 
3,3'-T 2 ORD 3-T I 8.9 188 21 
3,3' -T2S OR D 3 -T t S 0.3 353 1040 
Kinetic parameters were determined using liver microsomes from euthyroid rats in 0.1 M phosphate (pH 
7.2), 2 mM EDTA and 3-5 mM DTT. K m is expressed in t~M and Vma x in pmol/min per mg protein. 
Data are derived from Refs. [11-151. 
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iodothyronine [14]. It is remarkable that in contrast o the ORD of T4, which is 
blocked by sulfation, deiodination of rT3 is not affected [I 1], while ORD of 3,3 '-T2 
is even markedly stimulated by sulfate conjugation [15]. In the latter case this is as- 
sociated with a major decrease in the apparent Km value and a minor increase in 
Vmax (Table 1). 
In conclusion, the effect of sulfation of iodothyronines on their deiodination by 
ID-I strongly depends on the structure of the substrate. Sulfation markedly 
facilitates the IRD of T 4 and T 3, while ORD is either inhibited (T4) , unaffected 
(rT3) or clearly stimulated (3,3'-T2) by sulfoconjugation. The mechanism by which 
sulfation stimulates the type I deiodination of the various substrates remains 
unclear. In some cases ulfation primarily effects an increase in Vmax, in others there 
is a predominant decrease in the apparent Km value. Since rat and human ID-I are 
basic proteins [16,17], the facilitated eiodination of sulfated iodothyronines may be 
due to beneficial ionic interaction of the negatively charged sulfate group with pro- 
tonated residues in the enzyme active center [4]. The effect of conjugation on 
iodothyronine deiodination depends both on the site and the nature of the con- 
jugating roup. Type I deiodination of different iodothyronines is moderately stimu- 
lated by sulfonation of the c~NH2 group of these compounds, yielding non-naturally 
occurring sulfamates, but this effect is much less pronounced than that of sulfation 
[18]. We have also found that ID-I does not catalyze the deiodination of 
glucuronidated iodothyronines [19]. Finally, the effects of sulfation appears pecific 
for ID-I, since deiodination of sulfated substrates i not observed with either ID-II 
(unpublished work) or ID-III [20,21]. 
3. Production of iodothyronine sulfates in hepatocytes and in vivo 
3.1. T3S 
Studies with isolated rat hepatocytes have indicated that T 3 is metabolized to 
roughly similar extents by three pathways [19]: (a) glucuronidation (T 3 ~ T3G); (b) 
IRD, rapidly followed by successive sulfation and ORD (T 3 ~ 3,3'-T2 ~ 3,3'-T2S 
-- I-); and (c) sulfation, rapidly followed by successive IRD and ORD (T 3 -- T3S 
3,3'-TeS ~ I-). Under normal conditions, therefore, T3G and iodide are the main 
labeled products produced from [3'-125I]T3. If the sulfotransferase capacity of the 
cells is inhibited by SO42- depletion or by addition of ST inhibitors, I- production 
is largely inhibited, and 3,3'-T 2 (and 3,3'-T2G) accumulates. If on the other hand 
ID-I activity is inhibited with 6-propyl-2-thiouracil (PTU) or with iopanoic acid 
(lOP), I- production is also decreased, but this is now accompanied by the ac- 
cumulation of T3S and 3,3'-T2S [15,19,22]. 
After an intravenous (i.v.) injection of [125I]T3 to bile duct-cannulated rats, we 
found that [125I]T3G was the predominant radioactive product excreted in the bile 
[23]. Pretreatment of rats with PTU was found to have little effect on the biliary ex- 
cretion of T3G, but excretion of T3S and 3,3'-T2S was strongly increased [23]. 
While treatment of rats with DCNP had little effect on the biliary excretion of T 3 
metabolites compared with untreated rats, DCNP greatly diminished the PTU- 
induced excretion of T3S and 3,3'-T2S [23]. This is in agreement with the above- 
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mentioned in vitro findings, suggesting an important contribution of thermostable, 
DCNP-sensitive PSTs to hepatic T 3 sulfation. 
T3S is not only excreted in bile but, depending on the conditions, it may also be 
detected in blood. After i.v. administration of [125I]T 3to untreated rats, iodide is 
the predominant radioactive metabolite detected in plasma. However, if labeled T 3 
is injected in PTU-treated rats, the appearance of iodide in plasma is strongly 
decreased, while T3S and 3,3 '-T2S accumulate to levels that readily exceed serum T 3 
levels [24]. However, PTU does not decrease plasma T 3 clearance. Following an i.v. 
injection of [125I]T3S to control rats, the conjugate is cleared from plasma more 
rapidly than T 3. Iodide is again the main metabolite observed in plasma, and 20% 
of the dose is excreted as intact T3S in the bile [24]. Plasma T3S clearance is strong- 
ly inhibited by PTU, which is associated with a marked decrease in plasma iodide 
appearance as well as with an increase in the biliary excretion of intact T3S to 80% 
of the dose [24]. Therefore, the PTU-induced increase in plasma levels and biliary 
excretion of T3S after T 3 injection is explained by the inhibition of T3S deiodination 
rather than an increase in T 3 sulfation. 
We have developed a radioimmunoassay (RIA) for the measurement of T3S in 
serum [25]. Although the antiserum employed in this RIA showed high affinity and 
relatively high specificity for T3S, its significant cross-reactivity with T 3 and T 4 in 
combination with the high serum T 4 levels necessitated the isolation of the serum 
iodothyronine conjugate fraction prior to the assay. In agreement with the above- 
mentioned findings, RIA of serum T3S showed low but detectable l vels in normal 
rats, with a mean of 0.09 nM vs. 1.3 nM for T 3 [26]. Serum T3S markedly increased 
after treatment with PTU but not with methimazole, a thyrostatic drug that does not 
inhibit ID-I [26]. Results similar to those with PTU were obtained in animals treated 
with the X-ray contrast agent lOP that also inhibits ID-I [22]. The increase in serum 
T3S by PTU or lOP occurred even though serum T 3 was decreased, and was associ- 
ated with a similar increase in serum rT3 [22,26]. 
Analysis of human serum with this RIA demonstrated that T3S levels in normal 
subjects were mostly undetectable, i.e. < 0.1 nM vs. 2 nM for T 3 [27]. Serum T3S 
became barely detectable in healthy persons treated with T 3 (1 ~g/kg body wt./day), 
and showed an additional slight increase after administration of PTU, while serum 
T3S levels increased markedly after administration of lOP [27]. The increases in 
serum T3S induced by these regimens were strongly correlated with the increases in 
serum rT3, which is also largely cleared by type I deiodination, as serum rT 3 also 
showed a much larger increase after lOP than after PTU treatment [27]. Data 
reported by LoPresti et al. [28] indicate that in normal humans T3S is cleared ex- 
tremely rapidly from the circulation, and that this clearance is inhibited moderately 
by PTU administration but markedly by lOP administration as well as by fasting, 
another condition that may be associated with a decrease in hepatic ID-I activity 
[28]. 
The groups of Wu and Chopra have recently developed improved RIAs for T3S, 
the much greater specificities of which obviate the need to prepurify the samples, so 
that they can be applied directly to ethanol extracts of serum [29]. Using this RIA, 
Chopra et al. [29] also noted that serum T3S levels are low in normal subjects (< 0.1 
T.J. Visser / Chem.-Biol. Interact. 92 (1994) 293-303 299 
nM), and that they increase significantly after treatment of patients with IOP [291. 
They also found that the serum T3S/T 3 ratio is decreased in hyperthyroid patients 
and strongly increased inhypothyroid patients, in patients with non-thyroidal illness 
and in newborns, as determined in fetal cord serum [29]. Hepatic ID-I activity is 
known to be impaired in hypothyroidism, non-thyroidal il ness, and in the fetal 
stage, while enzyme activity is increased in hyperthyroidism [1,2]. Furthermore, x- 
tremely high T3 S levels have been detected by Wu et al. [30] in plasma, bile and 
meconium of fetal sheep (and in the allantoic fluid) at the time hepatic ID-I activity 
is still very low. Therefore, these recent data demonstrate hat also in humans and 
sheep, T3S levels accumulate o high levels, if deiodination of the conjugate by the 
type I deiodinase is inhibited. 
3.2. T4S 
Although in vitro tests of T4 as the substrate for tissue ST activities have been 
largely negative, evidence has been reported that T 4 undergoes significant sulfation 
in liver. Sato et al. [31] noted that T 4 was metabolized in primary cultures of rat 
hepatocytes by deiodination and by conjugation. Under normal conditions, ORD 
and IRD were the predominant pathways of T4 metabolism. However, if deiodina- 
tion was saturated at high substrate concentrations, conjugates were found to ac- 
cumulate, including T4S [31]. We have investigated the biliary excretion products of 
T4 after an i.v. injection of [125I]T4 to rats [32]. In control rats, T4G was the 
predominant radioactive compound in bile together with smaller amounts of TaG, 
rT3G and T4S. Pretreatment with PTU resulted in an increase in biliary T4G 
parallel with the increased plasma T4 retention, a marked decrease in T3G due to 
inhibited T4 to T 3 conversion, a marked increase in rT3G due to inhibited egrada- 
tion of rT3, and a large increase in T4S excretion [32]. Despite the negligible tissue 
T4 ST activities detected in vitro, these findings demonstrate that T 4 undergoes sig- 
nificant sulfation in vivo, and that T4S is predominantly cleared by type I 
deiodination. 
Although T4S is a significant biliary T4 metabolite in rats, we have not been able 
to detect his conjugate in serum after an i.v. injection of [125|]T 4 even in PTU- 
treated rats [32]. Using very sensitive and specific RIAs for T4S, Wu et al. [33] and 
Chopra et al. [34] have recently reported on the measurement of low concentrations 
of T4S in human serum. However, the mean T4S levels in normal human subjects 
differed markedly between the two studies, i.e. 100 and 19 pM, respectively (vs. 
100 nM for T4). Compared with serum from normal adults, increased T4S levels 
were observed in human amniotic fluid and in fetal cord serum obtained at the time 
of delivery [33,34]. Both groups also reported on an increase in serum T4S after ad- 
ministration of IOP to hyperthyroid patients [33,34]. Remarkably high levels of T4S 
were also detected in serum, bile and meconium of fetal sheep and in the allantoic 
fluid [30]. Together, these finding indicate that sulfation is a significant pathway for 
metabolism of T4 in humans, rats and sheep, and that the concentration f this con- 
jugate in body fluids builds up in conditions with low ID-I activity. 
3.3. rT3S 
We have found minor amounts of rT3S (and 3,3'-T2S) after incubation of rT3 
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with isolated rat hepatocytes, and only if this is done in the presence of PTU [35]. 
Normally, type I ORD is the foremost pathway of rT 3 metabolism in these cells. 
Although this converts rT 3 to 3,3'-T 2, little of the latter is normally observed, 
because it is rapidly further metabolized by successive sulfation and deiodination, 
as described above for hepatic T 3 metabolism [35]. 
Recently, Wu et al. [36] have also reported on the measurement of rT3S in 
human serum with a newly developed RIA for this sulfoconjugate, rT3S concentra- 
tions were low (in normal human subjects, i.e. mean 40 pM vs. 0.3 nM for rT 3, and 
no significant changes were noted in hypothyroid, hyperthyroid or pregnant subjects 
[36]. However, marked elevations were produced after administration of lOP to 
hyperthyroid patients [36]. Dramatic increases of rT3S were observed in fetal cord 
serum relative to serum rT3S in adults [36]. As mentioned above for T4S and T3S, 
high rT3S levels were also detected in serum, bile and meconium of fetal sheep and 
in the allantoic fluid [37]. Therefore, rT3 appears to be sulfated to some extent in 
humans and sheep, although this may be significant only if ID-I, the principal site 
of rT3 metabolism, is inhibited. 
4. Possible role of iodothyronine suifation 
Sulfation is a way to inactivate thyroid hormone: T3S does not bind to the T3 
receptor and is devoid of thyromimetic activity in several cell systems [38,39]. Fur- 
thermore, not only T3S but also T4S is rapidly degraded by ID-I. It has been 
postulated that sulfation of iodothyronines has an important function when ID-I ac- 
tivity is impaired, such as in non-thyroidal illness and during fetal development 
[20,21]. Under these conditions, T3S is not degraded in tissues with normally high 
ID-I activity, while the hormone is also protected by sulfation against degradation 
by ID-III [20,21]. Active T 3 may then be recovered from T3S through the action of 
sulfatases in tissues where hormone action is required or by bacterial sulfatases in 
the intestine. We have indeed demonstrated that bacterial sulfatases are important 
for the resorption of T 3 following biliary excretion of T3S [40-42]. Furthermore, 
significant hydrolysis of T3S has been detected in liver and brain microsomes in hu- 
mans and rats [43]. Santini et al. [44] have recently observed thyromimetic effects 
after administration of T3S to hypothyroid rats, with a potency of = 20% of that of 
T3, which appeared to be mediated by the liberation of T 3 from the injected T3S. 
An interesting aspect of these findings is that the biological effects of administered 
T3S in hypothyroid subjects are self-limited, since the initially impaired ID-I activ- 
ity in hypothyroidism is restored during T3S treatment, as is the deiodinative 
clearance of the conjugate [44]. However, the exact biological function of the dif- 
ferent iodothyronine sulfates in particular during fetal development remains to be 
fully explored. 
4. Conclusions 
Different ST isoenzymes appear to be involved in humans and in rats with the 
sulfation of T 3 and other iodothyronines. Under normal conditions, sulfation ac- 
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celerates the de iod inat ion of  the inner r ing of  T 4 and T 3 by the type I deiodinase in 
liver and probably  also in kidney, which results in the irreversible inact ivat ion of the 
hormone.  However,  under  condi t ions of low ID- I  activity, signif icant amounts  of  
T 3 may be recovered from T3S by sulfatases expressed in different tissues as well as 
by bacteria in the intestine. The former may be important  for the generat ion of local 
T 3 in tissues where active hormone is required, while the bacterial sulfatases are es- 
sential in the supply of  systemic T 3. Much further work remains to be done, how- 
ever, to explore the potential  role of T3S as a reservoir from which active T 3 is 
released when and where the active thyroid hormone is required. 
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